latest news releases from the newsroom
Atlas Copco Receives Breakthrough Order from the Liquid Natural Gas Market
STOCKHOLM, Sweden, April 18, 2005 (PRIMEZONE) -- Atlas Copco has received two large orders for integrally geared turbo compressors for a new application in the liquid natural gas (LNG) market. The total order value is about MSEK 240. The compressors will be used on board ships which will carry liquid natural gas from a large gas field in Qatar.
Maria Berggren New Vice President Human Resources at Biovitrum
STOCKHOLM, Sweden, April 18, 2005 (PRIMEZONE) -- Maria Berggren has been recruited as the new Vice President Human Resources at Biovitrum. Maria will be a member of the senior management team and will report directly to CEO Mats Pettersson. She will assume the post on July 1, 2005.
Telelogic Acquires U.S. Based Leader of Enterprise Architecture Tools
MALMO, Sweden, April 18, 2005 (PRIMEZONE) -- Telelogic AB (Stockholm Exchange:TLOG), today announced the acquisition of privately-held Popkin Software, the leading provider of enterprise architecture tools. Under the terms of the agreement, the consideration of USD 45 million will be paid in cash. Popkin's revenue 2004 was USD 19.1 million, 28% growth over 2003, with USD 2.5 million in pre-tax profit. Popkin currently employs 108 people.
Metro International: 2005 First Quarter Results Conference Call
BERTRANGE, Luxembourg, April 18, 2005 (PRIMEZONE) -- Metro International S.A. ("Metro"), the international newspaper group will announce its financial results for the first quarter ended 31 March 2005 on Wednesday, 20 April at 1:00 pm (CET). The company will host a conference call to present the results at 3:00 pm (CET). The call will also be webcast on Metro's website at www.metro.lu.
Metro Launches New Edition in Holland
BERTRANGE, Luxembourg, April 18, 2005 (PRIMEZONE) -- Metro International S.A. ("Metro"), the international newspaper group, today launched a new edition in Amsterdam. Its daily distribution will be 125,000 copies, combining 90,000 new copies and the 35,000 copies of the national Metro in Holland that are currently distributed in Amsterdam. These will now be converted into the local format. The Amsterdam edition will have a localized front cover and at least four extra pages of local news from Metro's own newsroom.
Winning features of Antisoma's AS1410 unveiled at AACR
ANAHEIM, Calif. and LONDON April 18, 2005 (PRIMEZONE) -- American Association of Cancer Research Meeting in Anaheim, California -- Cancer drug developer Antisoma plc (LSE:ASM) today presents the promising data that led to selection of AS1410 as its lead telomere targeting agent (TTA) for clinical trials. AS1410 more than halved the growth rate of established prostate cancer xenografts. It was the most effective TTA among a panel under evaluation, including the original TTA BRACO19, which had itself already shown promise in prostate and other cancer models. AS1410 retains the benefit of a rapid onset of action, with inhibition of tumour growth seen only seven days after starting treatment.
Cambodian Ventures Ltd.
Cambodian Ventures Limited Discusses the Potential for Precious Mineral Exploration in Cambodia
LOWELL, Mass. and PHNOM PENH, Cambodia, April 17, 2005 (PRIMEZONE) -- Cambodian Ventures Limited (Pink Sheets:CMBV), a junior mining company focused on exploration and mining of precious minerals in Cambodia, discussed the potential for economically viable precious mineralization deposits in Cambodia. Gary Fineberg, CEO of Cambodian Ventures Limited stated today: "There has been a lot of discussion on why anybody would choose to start a company in Cambodia to focus on exploration and mining of precious minerals. The answer is simple: tremendous ground floor opportunity." Gary outlined the following eleven reasons why Cambodian Ventures is focused on exploring for precious mineralization in Cambodia.
Integra LifeSciences Holdings Corp.
Integra NeuroSciences Launches Suturable DuraGen Dural Regeneration Matrix
PLAINSBORO, N.J., April 17, 2005 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced it has received 510(k) clearance from the United States Food and Drug Administration to market the Suturable DuraGen(TM) Dural Regeneration Matrix in the United States. Suturable DuraGen, the third generation in Integra LifeSciences' line of absorbable onlay collagen matrix grafts for cranial and spinal dural repair, provides the surgeon with the ability to use the graft as either an onlay graft or as a sutured graft.